Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
Recently, a new drug called Gefapixant passed phase III clinical trials for cough suppression
in patients with chronic cough. The goal of this clinical trial is to investigate the effect
of acute and prolonged administration of the drug Gefapixant on cough-related brain activity
in patients with chronic cough. The main question it aims to answer is: does the mechanism of
action of Gefapixant on the brainstem and brain circuits regulating cough differ between
acute and prolonged therapy in people with chronic cough?
Participants have their brain activity and their sensitivity to cough-inducing substances
measured as well as complete questionnaires about their cough before and while taking daily
Gefapixant.
Phase:
Early Phase 1
Details
Lead Sponsor:
Stuart Mazzone
Collaborators:
Melbourne Health Merck Sharp & Dohme LLC Monash University